Dermal Hypersensitivity Reaction to Semaglutide: Two Case Reports
Semaglutide is a glucagon-like peptide-1 (GLP-1) analog that was FDA-approved in 2017 for treatment of type II diabetes and in 2021 for treatment for chronic weight management in adults with obesity or overweight with at least one weight-related condition.1 Due to its longer duration of action, it is typically administered subcutaneously once weekly. The safety profile of semaglutide is similar to …
Semaglutide is a glucagon-like peptide-1 (GLP-1) analog that was FDA-approved in 2017 for treatment of type II diabetes and in 2021 for treatment for chronic weight management in adults with obesity or overweight with at least one weight-related condition.1 Due to its longer duration of action, it is typically administered subcutaneously once weekly. The safety profile of semaglutide is similar to … Continue reading "Dermal Hypersensitivity Reaction to Semaglutide: Two Case Reports"
INTRODUCTION
Periocular basal cell carcinoma (BCC) is the most common eyelid malignancy concomitant with ocular morbidity and quality of life impact.1,2 Orbital invasion occurs in 2% of cases and poses challenges for management.1,3 JDD authors highlight a multidisciplinary approach to the treatment of advanced periocular BCC.
CASE
JDD authors discuss a 56-year-old male who presente … 
Mastocytosis is a group of disorders characterized by the pathologic accumulation of mast cells in various tissues. One example of mastocytosis is urticaria pigmentosa, which presents with mastocytomas that can cause hives and, when irritated, pruritus. To the authors' knowledge, they are describing the first case of urticaria pigmentosa without pruritus. The patient had a positive Darier' … 
ABSTRACT
Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma, and extranodal involvement is seen in approximately 40% of cases. However, cases involving the skin and muscle are rare, and skin manifestations most commonly present as plaques, papules, small nodules, or ulcers. In this report, JDD authors Lauren E. Merz MD MSc, Christopher B. Hergott MD PhD, and Reb … 
Introducing the April 2024 Editorial Highlights from the Journal of Drugs in Dermatology! This month's issue is packed with groundbreaking research and insights into dermatologic treatments and practices. From original articles exploring innovative therapies for conditions like photoaging and acne vulgaris to case reports shedding light on rare dermatologic phenomena, this issue offers a comprehen … 